Livmoniplimab plus Budigalimab for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two investigational drugs, livmoniplimab and budigalimab, given together by IV for adults with advanced liver cancer (HCC) that cannot be removed by surgery or has spread. The study aims to see if this combination shrinks tumors and helps people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your cancer has been confirmed by a biopsy, other lab tests, or by specific medical guidelines for people with cirrhosis.
- Your liver cancer is at a stage called BCLC Stage B or C.
- Your liver function is relatively good, with a Child-Pugh score of 5, 6, or 7 (Class A or B7).
- You are able to do most daily activities on your own (ECOG performance status 0 or 1).
- You have not received any prior systemic treatment (such as chemotherapy or targeted therapy) for your liver cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
This Phase 2/3 study tests whether combining rulonilimab with lenvatinib can control unresectable advanced liver cancer (HCC) that cannot be removed by surgery or treated locally. You may be considered if you have not had prior whole-body (systemic) cancer treatments and your organs and blood counts are strong enough.
This trial tests a combination of three drugs—valemetostat, atezolizumab, and bevacizumab—for people with advanced liver cancer (HCC) who have not had systemic treatment before. The goal is to see if this combination can shrink tumors or slow disease progression.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
This trial tests a new combination of two immune system drugs (livmoniplimab and budigalimab) plus standard chemotherapy compared to the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated yet. The goal is to see if the new combination works better at controlling the cancer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.